Aim:Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by inattention (IA), hyperactivity, and impulsivity. In 2022, the Japanese version of the ADHD Rating Scale-5 (ADHD-RS-5) was released based on DSM-5. Although there are several changes compared to the previous version, few clinical studies have been conducted using the ADHD-RS-5. This study aimed to re-evaluate ADHD-related characteristics by age group in pediatric psychiatric outpatients, using the ADHD-RS-5 regardless of diagnosis, and compare these findings with previous research. Methods:Participants were all patients aged 5-17 years who visited the Psychiatry Clinic of Tokiwa Hospital or the Tokiwa Child Development Center (Child Psychiatry Clinic) during the study period. Of 503 children, 452 met the inclusion criteria. Primary caregivers completed the ADHD-RS-5. Symptom and functional impairment scores were compared by ADHD diagnosis and age group. In the ADHD group, scores were also compared based on pharmacological treatment. Results:IA and hyperactivity-impulsivity (HI) scores were significantly higher in the ADHD group. Functional impairment scores did not differ significantly in some age groups. HI scores were lower in older age bands, whereas IA scores did not differ significantly across age groups; the cross-sectional patterns are compatible with relative stability of inattentive symptoms but do not establish longitudinal persistence. Pharmacological treatment was not linked to symptom scores but was associated with higher impairment scores. Conclusion:Our findings using the ADHD-RS-5 showed results consistent with previous reports regarding age-specific symptom characteristics of ADHD, while also providing new insights into treatment options for ADHD. Clinicians may consider both symptom severity and functional impact when initiating pharmacotherapy. Given medication approval from age 6 in Japan, accurate assessment and diagnosis remain essential, and the ADHD-RS-5 may support decision-making when interpreted alongside clinical judgment and multi-informant input.
Background:Pulmonary arterial hypertension (PAH) is characterized by a progressive increase in pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR), imposing an increased workload on the right ventricle and ultimately leading to right heart failure. Macitentan is a potent dual endothelin receptor antagonist that blocks both endothelin receptor subtypes A and B, and is approved for adult patients with PAH, but evidence in pediatric PAH patients is limited. Methods and Results:This was an open-label, multicenter, Phase III study enrolling Japanese pediatric PAH patients aged ≥3 months to <15 years. A total of 7 patients were enrolled. Efficacy was evaluated by assessing pulmonary hemodynamics after 24 weeks of treatment, and safety was assessed over a 52-week period. The geometric mean fold change in PVR index (PVRI) at Week 24 was 59.43%, which met the prespecified success criterion of ≤81.6% (primary endpoint). Other pulmonary hemodynamic parameters, including mean PAP, mean right atrial pressure, and total pulmonary resistance, also showed improvement. Additionally, at Week 52, functional outcomes such as 6-minute walk test performance and quality-of-life reports, demonstrated a trend toward improvement. Safety findings were favorable, with no unexpected concerns among the 7 treated participants. Most adverse events were mild to moderate in severity, and none were considered related to macitentan. Conclusions:Macitentan showed clinically meaningful reduction in PVRI and improved pulmonary hemodynamics in Japanese pediatric patients with PAH, with a favorable safety profile over 52 weeks of treatment.